These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 31544849)

  • 1. Design and Production of Bispecific Antibodies.
    Wang Q; Chen Y; Park J; Liu X; Hu Y; Wang T; McFarland K; Betenbaugh MJ
    Antibodies (Basel); 2019 Aug; 8(3):. PubMed ID: 31544849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
    Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
    MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of Bispecific Antibodies by Fc Heterodimerization and their Application.
    Chen Z; Wang L; Xu T; Wang Q; Kang L; Zhao Q
    Curr Pharm Biotechnol; 2016; 17(15):1324-1332. PubMed ID: 27758688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering therapeutic bispecific antibodies using CrossMab technology.
    Klein C; Schaefer W; Regula JT; Dumontet C; Brinkmann U; Bacac M; Umaña P
    Methods; 2019 Feb; 154():21-31. PubMed ID: 30453028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.
    Klein C; Sustmann C; Thomas M; Stubenrauch K; Croasdale R; Schanzer J; Brinkmann U; Kettenberger H; Regula JT; Schaefer W
    MAbs; 2012; 4(6):653-63. PubMed ID: 22925968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.
    Liu H; Saxena A; Sidhu SS; Wu D
    Front Immunol; 2017; 8():38. PubMed ID: 28184223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic bispecific antibody formats: a patent applications review (1994-2017).
    Godar M; de Haard H; Blanchetot C; Rasser J
    Expert Opin Ther Pat; 2018 Mar; 28(3):251-276. PubMed ID: 29366356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of CrossMAb technology for the generation of bi- and multispecific antibodies.
    Klein C; Schaefer W; Regula JT
    MAbs; 2016; 8(6):1010-20. PubMed ID: 27285945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.
    Surowka M; Schaefer W; Klein C
    MAbs; 2021; 13(1):1967714. PubMed ID: 34491877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are BiTEs the "missing link" in cancer therapy?
    Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
    Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
    Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
    Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
    Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
    Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.
    Harwood SL; Alvarez-Cienfuegos A; Nuñez-Prado N; Compte M; Hernández-Pérez S; Merino N; Bonet J; Navarro R; Van Bergen En Henegouwen PMP; Lykkemark S; Mikkelsen K; Mølgaard K; Jabs F; Sanz L; Blanco FJ; Roda-Navarro P; Alvarez-Vallina L
    Oncoimmunology; 2017; 7(1):e1377874. PubMed ID: 29296540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
    Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
    Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.